Hydroxyflutamide
Small moleculeexperimental
Hydroxyflutamide (HF, OHF) (developmental code name SCH-16423), or 2-hydroxyflutamide, is a nonsteroidal antiandrogen (NSAA) and the major active metabolite of flutamide, which is considered to be a prodrug of hydroxyflutamide as the active form. It has been reported to possess an IC50 of 700 nM for the androgen receptor (AR), which is about 4-fold less than that of bicalutamide. — Wikipedia
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2009 (NCT00913263)
Timeline
Indications
Studied for
Mechanism of action
- Androgen ReceptorINHIBITOR
AR inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1- Mol. weight
- 292.21 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaHydroxyflutamide ↗
- ChEMBLCHEMBL491 ↗
Also known as
- 2-hydroxyflutamide
- 2-hydroxyflutamide
- 2-hydroxyflutamide
- alpha, alpha, alpha-trifluoro-2-methyl-4'-nitro-m-lactotoluidide
- hydroxyflutamide
- oh-flutamide
- sch 16423
- sch-16423
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03348527 | Phase 2 | May 12, 2017 | CMX Research, Lidds AB |
| NCT02341404 | Phase 2 | May 1, 2012 | Lidds AB, Uppsala University |
| NCT00913263 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2009 | Lidds AB, University of Tampere |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lidds AB | For profit | 3 | 2 | 1 | 2009 |
| CMX Research | For profit | 1 | 1 | 1 | 2017 |
| University of Tampere | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Uppsala University | Academic/Hospital | 1 | 0 | 1 | 2012 |
4 organizations
Page 1 / 1